不同诊断场景下高级别胶质瘤神经病理评估的诊断准确性:DNA甲基化分析的附加价值
该回顾性诊断准确性研究纳入130例颅内占位手术患者,比较普通病理科与专科神经病理科评估的准确性,以EPIC DNA甲基化分类为参考标准。普通病理科敏感性79%、总体准确性84%,专科神经病理科敏感性100%、总体准确性99%,DNA甲基化分析可细化肿瘤分类。
要点
- 专科神经病理评估对高级别胶质瘤识别准确性高,与DNA甲基化参考分类高度一致。
- 非专科病理评估敏感性较低,本队列中可遗漏部分高级别胶质瘤。
- DNA甲基化分析可补充组织病理,细化胶质瘤分类并纠正部分误判。
核心结论
- 专科神经病理评估与EPIC DNA甲基化参考分类高度一致,非专科评估敏感性较低。
- DNA甲基化分析通过细化肿瘤分类提供补充诊断价值。
研究设计与样本
- 回顾性诊断准确性研究,从173例筛选记录中纳入130例颅内占位手术患者。
- 标本先后经普通病理科和专科神经病理科独立评估,并行Illumina EPIC DNA甲基化分类作为参考标准。
- 高级别胶质瘤(CNS WHO 3-4级)定义为阳性,其他病变为阴性。
主要发现
- 普通病理科有20例高级别胶质瘤分类与EPIC参考不一致(假阴性),其中13例初判为低级别胶质瘤、2例为其他颅内病变、5例为非肿瘤脑组织。
- 普通病理科敏感性79%、特异性100%、阳性预测值100%、阴性预测值62%、总体准确性84%。
- 专科神经病理科敏感性100%、特异性97%、阳性预测值99%、阴性预测值100%、总体准确性99%。
- 3例具体分类或二分类状态存在差异:2例高级别胶质瘤进一步细化为胶质母细胞瘤、IDH野生型、CNS WHO 4级;1例组织病理示增殖和核分裂活动的标本经DNA甲基化分类为无肿瘤脑组织。
临床怎么用
- 疑似高级别胶质瘤的手术标本应争取专科神经病理评估以提高诊断准确性。
- 对诊断不确定或需细化分类的病例,可结合DNA甲基化分析辅助决策。
局限性
- 研究为回顾性设计,样本为筛选后的130例,可能存在选择偏倚。
- 结果基于特定参考标准(EPIC DNA甲基化分类),外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate histopathological diagnosis is essential for the management of patients undergoing surgery for suspected high-grade glioma (HGG). We evaluated the diagnostic accuracy of pathological assessment performed in a general pathology department and a specialist neuropathology department, using EPIC-based DNA methylation classification as the operational reference standard. METHODS: This retrospective diagnostic accuracy study included 130 patients with complete results from three diagnostic assessments (selected from 173 screened records) with intracranial space-occupying lesions who underwent surgical biopsy or resection between May 2019 and February 2025. Tissue specimens were assessed in a general pathology department and subsequently evaluated independently in a specialist neuropathology department, followed by DNA methylation profiling using the Illumina Infinium MethylationEPIC BeadChip. HGGs (CNS WHO grades 3-4) were classified as positive and all other lesions as negative. RESULTS: Assessment in the general pathology department yielded 20 HGG classifications discordant with the EPIC reference (false negatives), including 13 tumors initially classified as low-grade gliomas, two as other intracranial lesions, and five as non-neoplastic brain tissue. Sensitivity was 79%, specificity 100%, positive predictive value 100%, negative predictive value 62%, and overall accuracy 84%. Specialist neuropathological assessment achieved a sensitivity of 100%, specificity of 97%, positive predictive value of 99%, negative predictive value of 100%, and overall accuracy of 99%. Three cases differed in specific classification or binary status: two HGG diagnoses were further refined as glioblastoma, IDH-wildtype, CNS WHO grade 4, while one specimen interpreted histopathologically as showing proliferative and mitotic activity was classified as tumor-free brain tissue by DNA methylation profiling. CONCLUSIONS: Specialist neuropathological assessment showed high agreement with the EPIC-based reference classification for HGGs, whereas assessment outside a specialized neuropathology setting showed lower sensitivity for HGG identification in this selected cohort. DNA methylation profiling provides complementary diagnostic value by refining tumour classification.
引用
- Christoforou T, Elmuradova U, Hammersen S, et al. Diagnostic accuracy of neuropathological assessment across different diagnostic settings for high-grade gliomas: the added value of DNA methylation profiling. Acta Neurochir (Wien). 2026. PMID: 42931851. doi:10.1007/s00701-026-07078-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。